Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis


Current price
4.65 USD +0.03 USD (+0.65%)
Last closed 4.73 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 273 069 920 USD
Yield for 12 month -0.85 %
21.11.2021 - 28.11.2021

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel. Address: 2 Holzman Street, Rehovot, Israel, 7670402


WallStreet Target Price

11.5 USD

P/E ratio


Dividend Yield

Current Year

+129 339 000 USD

Last Year

+103 642 000 USD

Current Quarter

+37 934 000 USD

Last Quarter

+37 443 000 USD

Current Year

+46 703 000 USD

Last Year

+30 328 000 USD

Current Quarter

+14 803 000 USD

Last Quarter

+14 436 000 USD

Key Figures KMDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 22 800 000 USD
Operating Margin TTM 11.52 %
PE Ratio 36.3077
Return On Assets TTM 2.15 %
PEG Ratio 8.75
Return On Equity TTM 3 %
Wall Street Target Price 11.5 USD
Revenue TTM 151 526 000 USD
Book Value 5.18 USD
Revenue Per Share TTM 3.26 USD
Dividend Share
Quarterly Revenue Growth YOY 17.7 %
Dividend Yield
Gross Profit TTM 46 703 000 USD
Earnings Share 0.13 USD
Diluted Eps TTM 0.13 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 500 %
Profit Margin 4.07 %

Dividend Analytics KMDA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History KMDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation KMDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 36.3077
Forward PE 10.3306
Enterprise Value Revenue 1.6038
Price Sales TTM 1.5766
Enterprise Value EBITDA 62.6592
Price Book MRQ 1.1242

Financials KMDA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators KMDA

For 52 weeks

3.72 USD 5.85 USD
50 Day MA 4.81 USD
Shares Short Prior Month 5 115
200 Day MA 4.88 USD
Short Ratio 0.49
Shares Short 11 687
Short Percent 0.03 %